Oxford Biomedica PLC (LON:OXB), a global quality and innovation-led cell and gene therapy CDMO, has announced the launch of its new fast-track development and manufacturing offering, providing an expedited route to GMP manufacture for clients utilising lentiviral (LV) and adeno-associated viral (AAV) vectors.
Launched in response to growing client demand, OXB’s fast-track offering provides a cost-effective, accelerated option for biotechs with eligible programmes, using the Company’s proprietary inAAVate™ and LentiVector™ platforms. These faster timelines will help OXB’s clients maintain a competitive edge in the market, enabling them to achieve clinical and regulatory milestones earlier, ultimately leading to faster access to transformative treatments for patients.
OXB’s fast-track programme for AAV vectors can accelerate the pathway to GMP manufacture from an industry standard ~15 months to as little as seven months. Particularly suitable for wild type AAVs, this has been achieved through the use of a high-performance plug-and-play platform, reducing the need for a number of development steps while achieving high titers and more consistent performance at relevant development scales, and through OXB’s in-house expertise for accelerated analytical development and qualification.
For the manufacture of lentiviral vectors, OXB’s fast-track offering accelerates an industry-standard 12-18 month timeline to as little as nine months, through the use of platform datasets and advanced analytics, and proceeding directly from scale-down models into GMP manufacturing. Additional efficiencies are achieved through the integration of vector design, production, purification, and fill-finish, shortening timelines.
Through the launch of this offering specifically designed for innovative clients where time or financing is limited, OXB is extending the global reach of its inAAVate™ and LentiVector™ platforms, reinforcing OXB’s position as a trusted provider of viral vector development and manufacturing services.
Dr Sébastien Ribault, Chief Business Officer of Oxford Biomedica, said: “For emerging cell and gene therapy companies, viral vector development and manufacture represents a frequent bottleneck to clinical readiness, and issues can delay critical clinical milestones. The launch of our fast-track offering will make our proprietary inAAVate™ and LentiVector™ platforms accessible to a wider range of clients who are looking for an expedited route to GMP manufacture and the clinic, cutting industry standard development timelines by up to 50%.”
